Disparities in Clinical Trial Enrollment for Patients with Hematologic Malignancies - a 15-Year Princess Margaret Cancer Centre Experience

• Published in: Blood 2024-11, Vol.144, p.401-401
• Main Authors: Suleman, Adam, Santiago, Anna, Pittman, Tyler, Shapiro, Gilla, Prica, Anca, Bhella, Sita D., Cole, Heather, Zeman, Katherine, Rodin, Gary, Sellmann, Susanna, Oza, Amit, Jones, Jennifer, Conti, Rena M, Rosenthal, Meredith, Rodin, Danielle
• Format: Article
• Language: English
• ISSN: 0006-4971
• DOI: 10.1182/blood-2024-194613

Background: Clinical trial (CT) participation is critical to advance the management of hematologic malignancies (HM) and is an important indicator of quality of care. Disparities in CT participation are important health inequities that limit the generalizability of study findings. Within Canada, sociodemographic disparities in clinical trial participation for patients with HM are not well understood. Therefore, in this study, we aimed to identify factors associated with CT enrollment of patients with HM at a large comprehensive cancer centre. Methods: We performed a retrospective study of CT enrollment among new patients with HM who were seen in consultation from 2006 to 2019 with follow-up until 2021 at Princess Margaret Cancer Centre in Toronto, Canada. CT enrollment was categorized as a binary outcome at 2-, 5- and 10-year follow-up from the date of initial consultation. Demographic data collected included sex, age at diagnosis, language, distance to hospital, access to a primary care provider, and marginalization dimensions. The 2016 Ontario Marginalization Index was used, capturing area-level data on four key dimensions of marginalization: residential instability, material deprivation, dependency, and ethnic concentration. Univariable and multivariable logistic regression models were used to assess the impact of baseline variables on CT enrollment. Cumulative incidence of trial enrollment was measured using death as the competing event, and competing risk regression analyses were performed to assess associated factors as a sensitivity analysis. Results: A total of 21,286 new HM patients were seen at PM during the study period of whom 1,692 (7.9%) were enrolled in a CT at 2 years from initial consultation, 1,954 (9.2%) at 5 years, and 2,059 (9.7%) at 10 years. The cumulative instance of CT enrollment at 10-years was 2,592 (12.2%), with 2059 patients (79.4%) having enrolled in 1 trial, 411 in 2 trials (15.9%) and 122 in 3 or more trials (4.7%). Of these, 34% were phase I trials, 29% were phase II trials, 23% were phase III/IV trials, and 14% had missing phase data. Most CTs (56%) were industry sponsored. A majority of CT participants had myeloid diseases (1283/2592, 50%), and fewer patients had lymphoma (834/2592, 32%) or myeloma (475/2592, 18%). Most patients enrolled were age 40-69 (66%, n=1357), 16% were 70 years and 58% (n = 1187) were male. Patients enrolled in CT had lower rates of material deprivation (p